Overview

Peanut Oral Immunotherapy and Anti-Immunoglobulin E (IgE) for Peanut Allergy

Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether the addition of anti-IgE treatment will make peanut oral immunotherapy safer, more tolerable, and more effective in treating peanut allergy.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of North Carolina, Chapel Hill
Collaborator:
Genentech, Inc.
Treatments:
Omalizumab